VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  05/26 04:00:00 pm EDT
0.3860 USD   +1.58%
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade

01/13/2022 | 04:00pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BABYLON HOLDINGS LIMITED 0.37% 0.9999 Delayed Quote.-82.85%
DENALI THERAPEUTICS INC. 5.36% 24.16 Delayed Quote.-45.83%
JOURNEY MEDICAL CORPORATION 0.00% 4.3 Delayed Quote.-20.07%
NASDAQ COMP. 2.68% 11740.65 Real-time Quote.-24.96%
ON SEMICONDUCTOR CORPORATION 5.49% 59.33 Delayed Quote.-12.65%
VAXCYTE, INC. 0.94% 25.86 Delayed Quote.8.70%
VYNE THERAPEUTICS INC. 1.58% 0.386 Delayed Quote.-62.16%
All news about VYNE THERAPEUTICS INC.
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Revenue $178,000
MT
05/12VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
05/12VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Up..
AQ
05/12NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
05/10VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,66x
Yield 2022 -
Capitalization 22,4 M 22,4 M -
Capi. / Sales 2022 51,6x
Capi. / Sales 2023 5,32x
Nbr of Employees 28
Free-Float 91,0%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,39 $
Average target price 5,80 $
Spread / Average Target 1 403%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-62.16%22
JOHNSON & JOHNSON4.90%472 231
PFIZER, INC.-8.57%302 932
ROCHE HOLDING AG-12.16%282 336
ELI LILLY AND COMPANY13.48%282 164
ABBVIE INC.11.20%266 074